Ascensia Diabetes Care Receives Amended Health Canada License for Contour® Next Link 2.4 for Use With the Minimed™ 670g Insulin Pump System
MISSISSAUGA, ON, Oct. 17, 2018 /CNW/ - Ascensia Diabetes Care today announced the receipt of an amended license from Health Canada for the CONTOUR® NEXT LINK 2.4 blood glucose meter to be used with the new Medtronic MiniMed™ 670G insulin pump system with SmartGuard™ algorithm.
"Achieving another important regulatory milestone demonstrates Ascensia's ongoing commitment to delivering innovative products that help improve the lives of individuals affected by diabetes," said Annika Pawaroo, Country Division Head of Canada, Ascensia Diabetes Care. "We are proud to be able to offer new options for Canadians living with diabetes who need and want meters that are accurate."
Type 1 diabetes affects about 300,000 Canadians1. The primary goal of diabetes management is to control blood glucose levels and ensure they are kept within a normal range. When blood glucose levels get too high (hyperglycemia) or too low (hypoglycemia), it can lead to serious complications.
The CONTOUR® NEXT LINK 2.4 is the exclusive licensed blood glucose meter designed to connect wirelessly with the Medtronic MiniMed™ 670G insulin pump system. The CONTOUR® NEXT LINK 2.4 meter provides highly accurate blood glucose results that can be used for the insulin dosing and calibration of the Guardian™ Sensor 3, the continuous glucose monitoring (CGM) sensor. Accurate results also help people with diabetes reduce the risk of hypo- and hyperglycemia2. The meter provides proven accuracy3 utilizing the highly accurate CONTOUR® NEXT test strips.
The MiniMed™ 670G insulin pump system is the world's first self-adjusting insulin pump system. It is designed to help people with diabetes achieve better glucose control, with its advanced SmartGuard™ Auto Mode algorithm, by automatically monitoring glucose and providing the appropriate basal insulin doses for people 7 years of age and older with type 1 diabetes. The system will also automatically suspend insulin delivery when sensor glucose levels reach a pre-set low limit, and resumes insulin delivery once sensor glucose levels recover.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.
Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.
For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.
Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license. For further information please visit ContourNextLink24.ca.
For further information on the MiniMed™ 670G System, please visit Medtronic diabetes at www.medtronicdiabetes.ca
CONTOUR® is a registered trademark of Ascensia Diabetes Care Holdings AG.
MiniMed and SmartGuard are trademarks of Medtronic
|1||Canadian Diabetes Association. The prevalence and costs of diabetes. December 2009.|
|2||Budiman ES et al. J Diabetes Sci Technol 2013;7(2):365–380.|
|3||Bailey TJ et al. Accuracy, Precision, and User Performance Evaluation of the CONTOUR® NEXT LINK 2.4|
SOURCE Ascensia Diabetes Care